Render Target: STATIC
Render Timestamp: 2024-10-09T11:09:32.270Z
Commit: f04ddd7fea9fb3592f59f61482fcb94610d25cbe
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

CD96 (E1Y2Z) Rabbit mAb #66102

Filter:
  • WB
  • IF
  • F

    Supporting Data

    REACTIVITY M
    SENSITIVITY Endogenous
    MW (kDa) 100-200
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    • IF-Immunofluorescence 
    • F-Flow Cytometry 
    Species Cross-Reactivity Key:
    • M-Mouse 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    Immunofluorescence (Frozen) 1:50 - 1:200
    Immunofluorescence (Immunocytochemistry) 1:200 - 1:800
    Flow Cytometry (Fixed/Permeabilized) 1:50 - 1:200
    Flow Cytometry (Live) 1:50 - 1:200

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    CD96 (E1Y2Z) Rabbit mAb recognizes endogenous levels of total CD96 protein. This antibody does not cross-react with human CD96 protein.

    Species Reactivity:

    Mouse

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with recombinant protein specific to the extracellular domain of mouse CD96 protein.

    Background

    Cluster of Differentiation 96 (CD96), also known as T cell-activated increased late expression protein (TACTILE), is a heavily glycosylated type I transmembrane protein belonging to the immunoglobulin superfamily (1-3). CD96 is expressed on peripheral T cells and natural killer (NK) cells, and is strongly upregulated on these cell types after activation (1,4). It is also expressed on transformed T cells, and at very low levels on activated B cells (1,5,6). CD96 interacts with the receptor ligand PVR (CD155), and is involved in adhesion of activated T and NK cells to target cells during the late phase of the immune response (2,4). CD96 competes with DNAM-1 (CD226) for binding to PVR (CD155) in order to negatively regulate T and NK cell activity, and thus blockade of CD96 in order to induce anti-tumor immune responses is investigated for potential immunotherapeutic intervention in cancer (7-9). Alternative splicing occurs at this locus, and two transcript variants encoding distinct isoforms with variable functions have been identified (1,10).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.